EU approves Eylea for Visual Impairment RVO-Regeneron Pharma

Regeneron Pharmaceuticals has announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo). The new indication includes macular oedema following branch retinal vein occlusion (brvo) in addition to the previously approved indication of macular oedema secondary to central retinal vein occlusion (crvo).

The recommended treatment approach in the European Union is to initiate the therapy with one injection per month, continuing monthly treatment until maximum visual acuity is achieved and/or there are no signs of disease activity. Treatment may then be continued with a treat and extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes. Approval is based on positive data from the phase III VIBRANT study in patients with visual impairment due to macular oedema secondary to brvo.